Dashan Ai

747 total citations
21 papers, 294 citations indexed

About

Dashan Ai is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Dashan Ai has authored 21 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Dashan Ai's work include Esophageal Cancer Research and Treatment (19 papers), Gastric Cancer Management and Outcomes (10 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Dashan Ai is often cited by papers focused on Esophageal Cancer Research and Treatment (19 papers), Gastric Cancer Management and Outcomes (10 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Dashan Ai collaborates with scholars based in China, France and India. Dashan Ai's co-authors include Jiaying Deng, Kuaile Zhao, Yun Chen, Jinjun Ye, Qi Liu, Zhengfei Zhu, Hongcheng Zhu, Shengping Wang, Junqiang Chen and Guoren Zhou and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Dashan Ai

21 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dashan Ai China 9 202 199 132 27 22 21 294
Shi-Liang Liu China 13 210 1.0× 188 0.9× 100 0.8× 18 0.7× 40 1.8× 17 309
Nadim Bashir United Kingdom 5 232 1.1× 233 1.2× 106 0.8× 23 0.9× 21 1.0× 5 316
Patty H. Spruit Netherlands 5 333 1.6× 316 1.6× 102 0.8× 46 1.7× 22 1.0× 5 428
Matthew J. Iott United States 6 113 0.6× 132 0.7× 235 1.8× 22 0.8× 16 0.7× 11 275
Alison Price United Kingdom 8 153 0.8× 150 0.8× 158 1.2× 19 0.7× 17 0.8× 17 322
Hisami Fukuda Japan 4 228 1.1× 258 1.3× 42 0.3× 12 0.4× 50 2.3× 9 328
Meiqing Xu China 11 139 0.7× 218 1.1× 55 0.4× 17 0.6× 90 4.1× 38 337
Kilian Salerno May United States 7 50 0.2× 88 0.4× 136 1.0× 23 0.9× 21 1.0× 12 233
Seok-Byung Lim South Korea 9 239 1.2× 149 0.7× 394 3.0× 101 3.7× 26 1.2× 13 444

Countries citing papers authored by Dashan Ai

Since Specialization
Citations

This map shows the geographic impact of Dashan Ai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dashan Ai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dashan Ai more than expected).

Fields of papers citing papers by Dashan Ai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dashan Ai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dashan Ai. The network helps show where Dashan Ai may publish in the future.

Co-authorship network of co-authors of Dashan Ai

This figure shows the co-authorship network connecting the top 25 collaborators of Dashan Ai. A scholar is included among the top collaborators of Dashan Ai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dashan Ai. Dashan Ai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ai, Dashan, Shengnan Hao, Wenbin Shen, et al.. (2024). Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial. EClinicalMedicine. 69. 102471–102471. 16 indexed citations
3.
Liu, Qi, Dashan Ai, Ke Chen, et al.. (2023). Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation. Current Treatment Options in Oncology. 24(11). 1568–1579. 7 indexed citations
4.
Xu, Bing, Xiaofei Zhang, Hui Chen, et al.. (2023). Immune characteristics and genetic markers of esophageal cancer by single-cell analysis: implications for immunotherapy. Journal of Thoracic Disease. 15(4). 1805–1822. 3 indexed citations
5.
Ai, Dashan, Yun Chen, Qi Liu, et al.. (2023). Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9). Radiation Oncology. 18(1). 26–26. 3 indexed citations
6.
Zhu, Hongcheng, Zezhou Wang, Miao Mo, et al.. (2023). Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020. Thoracic Cancer. 14(11). 992–1003. 23 indexed citations
7.
8.
Li, Fangfang, Dashan Ai, Yun Chen, et al.. (2023). Less Irradiation to Lymphocyte-Related Organs Reduced the Risk of G4 Lymphopenia in Esophageal Cancer: Re-Analysis of Prospective Trials. The Oncologist. 28(8). e645–e652. 5 indexed citations
9.
Liu, Qi, Junqiang Chen, Lin Yu, et al.. (2023). Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. ˜The œLancet. Gastroenterology & hepatology. 9(1). 45–55. 28 indexed citations
10.
Chen, Yun, Zhengfei Zhu, Weixin Zhao, et al.. (2022). Long-Term Results of a Phase 2 Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients Who Were Elderly or With Serious Comorbidities. Frontiers in Oncology. 12. 839765–839765. 1 indexed citations
11.
Jiang, Hongli, Peng Zhang, Kai Gu, et al.. (2022). Cost-effectiveness analysis of a community-based colorectal cancer screening program in Shanghai, China. Frontiers in Public Health. 10. 986728–986728. 4 indexed citations
12.
Zhang, Zhi, Jinjun Ye, Hui Li, et al.. (2022). Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial. Frontiers in Immunology. 13. 1031171–1031171. 32 indexed citations
13.
Hao, Shengnan, Xiangyan Zhang, Litao Han, et al.. (2022). PD-1 Inhibitor Enhanced Radiosensitivity by Reactivating T Cells and Inducing G2/M Phase Arrest in Esophageal Squamous Cell Carcinoma. Radiation Research. 198(5). 458–466. 4 indexed citations
14.
Ai, Dashan, Yun Chen, Qi Liu, et al.. (2021). The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial. Frontiers in Oncology. 11. 669575–669575. 3 indexed citations
15.
Chu, Li, Yun Chen, Qi Liu, et al.. (2021). A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11). The Oncologist. 26(6). e925–e935. 25 indexed citations
16.
Li, Xiaoyu, Dashan Ai, Yun Chen, et al.. (2021). Cancer of Pharyngoesophageal Junction: A Different Subtype From Hypopharyngeal and Cervical Esophageal Cancer?. Frontiers in Oncology. 11. 710245–710245. 1 indexed citations
17.
Liu, Qi, Zhengfei Zhu, Yun Chen, et al.. (2020). Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 108(3). 707–715. 36 indexed citations
18.
Ai, Dashan, Yun Chen, Qi Liu, Jiaying Deng, & Kuaile Zhao. (2019). The effect of tumor locations of esophageal cancer on the metastasis to liver or lung. Journal of Thoracic Disease. 11(10). 4205–4210. 16 indexed citations
19.
Chu, Li, Fei Liang, Jiaying Deng, et al.. (2019). A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC). Annals of Oncology. 30. ix177–ix177. 2 indexed citations
20.
Ai, Dashan, et al.. (2017). Patterns of distant organ metastases in esophageal cancer: a population-based study. Journal of Thoracic Disease. 9(9). 3023–3030. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shi-Liang Liu Breakdown of academic impact, for papers by Nadim Bashir Breakdown of academic impact, for papers by Patty H. Spruit Breakdown of academic impact, for papers by Matthew J. Iott Breakdown of academic impact, for papers by Alison Price Breakdown of academic impact, for papers by Hisami Fukuda Breakdown of academic impact, for papers by Meiqing Xu Breakdown of academic impact, for papers by Kilian Salerno May Breakdown of academic impact, for papers by Seok-Byung Lim
Rankless by CCL
2026